Leflunomide as adjuvant treatment of dermatomyositis.
We report 3 cases of recalcitrant dermatomyositis that responded to the addition of daily leflunomide, a novel immunomodulatory drug that is currently used to treat rheumatoid arthritis. In our patients, leflunomide proved both safe and effective as adjuvant therapy in treating dermatomyositis.
Boswell
J Scott
JS
Department of Dermatology, University of Texas Southwestern Medical Center at Dallas, USA.
Costner
Melissa I
MI
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003882:Dermatomyositis / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000077339:Leflunomide; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D003879:Dermatologic Agents; D005938:Glucocorticoids; D007555:Isoxazoles; D006886:Hydroxychloroquine; D000077339:Leflunomide; D011241:Prednisone; D008727:Methotrexate